ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TAKING LOW-DOSE SACUBITRIL-VALSARTAN.

Main Article Content

Kaleem Ullah Sheikh
Abeer Sarfaraz
Amna Farooq
Sanjana Devi
Sana Shoaib

Abstract

Objective: To examine the impact of administering low-dose sacubitril-valsartan on the quality of health in individuals suffering from heart failure and reduced ejection fraction.
Methodology:  It is a prospective, cohort study comprising n=77 heart failure patients from a Tertiary Care Hospital with low ejection fraction. An FDA-approved KCCQ questionnaire was used for data collection at admission and after a 6-week follow-up. Descriptive statistics were reported in terms of percentage and mean± Std. dev. For mean comparison paired t-test was used. P value <0.05 was considered statistically significant.
Results:  Out of 77 patients, 28 (36.4%) were women and 49 (63.6%) were men. The study included participants with an average age of 60.05±11.80 years. Among the participants, 68.8% had hypertension and 51.9% had diabetes. 29.9% of the patients included had an EF of 30%, 49.3% had it between 31-39%, and 20.8% had an EF of 40%. Regarding classification by New York Heart Association (NYHA), before initiating Sacubitril/Valsartan, around 84.4% of patients were categorized as class 3, while 15.6% as class 4. Six weeks after therapy 79.2% of patients improved to functional class 2 and 20.8% to class 3. Statistical analysis revealed a significant difference
in Kansas City Cardiomyopathy Questionnaire (KCCQ) scores of heart failure patients when comparing scores prior to and after receiving treatment of sacubitril/valsartan, 24/26mg BID.
Conclusion:  The study showed that patients with heart failure having a low ejection fraction experienced an improvement in quality of life as judged by KCCQ scores even while using sacubitril-valsartan at a low dose.

Article Details

How to Cite
1.
Sheikh KU, Sarfaraz A, Farooq A, Devi S, Shoaib S. ASSESSMENT OF HEALTH-RELATED QUALITY OF LIFE IN PATIENTS WITH HEART FAILURE AND REDUCED EJECTION FRACTION TAKING LOW-DOSE SACUBITRIL-VALSARTAN. J Postgrad Med Inst [Internet]. 2023 Aug. 27 [cited 2024 Jun. 23];37(3):166-70. Available from: https://jpmi.org.pk/index.php/jpmi/article/view/3220
Section
Original Article

References

Velazquez EJ, Morrow DA, DeVore AD, Ambrosy AP, Duffy CI, McCague K, et al Rationale, and design of the comparison of sacubitril/valsartan versus Enalapril on Effect on nt-pRo-bnp in patients stabilized from an acute Heart Failure episode (PIONEER-HF) trial. Am Heart J. 2018; 198:145-151. DOI.10.1016/j. ahj.2018.01.004.

Dewan P, Docherty KF, McMurray JJ. Sacubitril/valsartan in Asian patients with heart failure with reduced ejection fraction. Korean Circ J. 2019;49(6):469- 84. DOI:10.4070/kcj.2019.0136.

Kobalava Z, Kotovskaya Y, Averkov O, Pavlikova E, Moiseev V, Albrecht D, et al. Pharmacodynamic and pharmacokinetic profiles of sacubitril/valsartan (LCZ 696) in patients with heart failure and reduced ejection fraction. Cardiovasc Ther. 2016;34(4):191-8. DOI .10.1111/12183.

Erreira JP, Girerd N, Rossignol P, Zannad F. Geographic differences in heart failure trials. Eur J Heart Fail. 2015;17(9):893- 905. DOI.10.1002/ejhf.326.

Khariton Y, Fonarow GC, Arnold SV, Hellkamp A, Nassif ME, Sharma PP, et al. Association between sacubitril/ valsartan initiation and health status outcomes in heart failure with reduced ejection fraction. J Am Coll Cardiol H Fail. 2019;7(11):933-41.

Jalal Z, Cabdi S, Khan N, Dorsch M, Gill N, Stalker F, et al. Sacubitril/valsartan in patients with symptomatic chronic heart failure with reduced ejection fraction. J Pharm Pract. 2019;1(4):182-92. DOI.10.12968/jprp.2019.1.4.182

Liang L, Bin-Chia Wu D, Aziz MI, Wong R, Sim D, Leong KT, et al. Cost-effectiveness of sacubitril/valsartan versus enalapril in patients with heart failure and reduced ejection fraction. J Med Econ. 2018 ;21(2):174-81. DOI.10.1080/2017.1387119.

Spertus JA, Jones PG. Development and validation of a short version of the Kansas City Cardiomyopathy Questionnaire. Circ Cardiovasc Qua Outcomes. 2015;8(5):469-76. DOI: 10.1161/CIR-COUTCOMES.115.001958

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18(8):891-975.

Giallauria F, Vitale G, Pacileo M, Di Lorenzo A, Oliviero A, Passaro F, et al. Sacubitril/valsartan improves autonomic function and cardiopulmonary parameters in patients with heart failure with reduced ejection fraction. J Clin Med. 2020;9(6):1897. DOI: 10.3390/ jcm9061897

Ferreira JP, Duarte K, Graves TL, Zile MR, Abraham WT, Weaver FA, et al. Natriuretic peptides, 6-min walk test, and quality-of-life questionnaires as clinically meaningful endpoints in HF trials. J Am Coll Cardiol. 2016;68(24):2690- 707.

Alosco ML, Spitznagel MB, Cohen R, Sweet LH, Hayes SM, Josephson R, et al. Decreases in daily physical activity predict acute decline in attention and executive function in heart failure. J Card Fail 2015;21(4):339-46. DOI.10.1016/j.cardfail.2014.12.010.

Chang HY, Feng AN, Fong MC, Hsueh CW, Lai WT, Huang KC, et al. Sacubitril/ valsartan in heart failure with reduced ejection fraction patients: real world experience on advanced chronic kidney disease, hypotension, and dose escalation. J Cardiol. 2019;74(4):372-80. DOI.10.1016/j.jjcc.2019.03.010.

Spertus JA, Jones PG, Sandhu AT, Arnold SV. Interpreting the Kansas City Cardiomyopathy Questionnaire in clinical trials and clinical care: JACC state-of-the-art review. J Am Coll Cardiol. 2020;76(20):2379-90. DOI: 10.1016/j. jacc.2020.09.542

Campal JM, Del-Castillo H, Rivera BA, de Juan Bitria C, Urquia MT, Borque PS, et al. Improvement in quality of life with sacubitril//valsartan in cardiac resynchronization non-responders: The RESINA (RESynchronization plus an Inhibitor of Neprilysin/Angiotensin) registry. Cardiol J. 2021;28(3):402-10.

Proudfoot C, Studer R, Rajput T, Jindal R, Agrawal R, Corda S, et al. Real world effectiveness and safety of sacubitril/ valsartan in heart failure: a systematic review. Int J Cardiol. 2021;331:164-71. DOI: 10.1016/j.ijcard.2021.01.061

van den Berge JC, van Vark LC, Postmus D, Utens EM, Hillege HL, Boersma E, et al. Determinants of quality of life in acute heart failure patients with and without comorbidities: a prospective, observational study. Eur J Cardiovasc Nurs. 2022;21(3):205-12. DOI:10.1093/eurjcn/zvab061.

Lewis EF, Claggett BL, McMurray JJ, Packer M, Lefkowitz MP, Rouleau JL, et al. Health-related quality of life outcomes in PARADIGM-HF. Circ Heart Fail. 2017;10(8).e003430. DOI: 10.1161/ CIRCHEARTFAILURE.116.003430

Wachterman MW, Pilver C, Smith D, Ersek M, Lipsitz SR, Keating NL. Quality of end-of-life care provided to patients with different serious illnesses. JAMA Intern Med.2016;176(8):1095- 0 2 . D O I : 1 0 . 1 0 0 1 / j a m a i n t ernmed.2016.1200.

Turgeon RD, Barry AR, Hawkins NM, Ellis UM.Pharmacotherapy for heart failure with reduced ejection fraction and health related quality of life: a systematic review and meta analysis. Eur J Heart Fail. 2021;23(4):578-89.

Riaz M, Smith SM, Dietrich EA, Pepine CJ, Park H. Effectiveness of sacubitril/valsartan versus aldosterone antagonists in heart failure with reduced ejection fraction: A retrospective cohort study. Pharmacotherapy: J Human Pharmacol Drug Therap.2021;41(9):710-21. DOI:10.1002/phar.2610

Martens P, Belien H, Dupont M, Vandervoort P, Mullens W. The reverse remodeling response to sacubitril/ valsartan therapy in heart failure with reduced ejection fraction. Cardiovasc Ther. 2018;36(4). e12435. DOI: 10.1111/1755-5922.12435

Tsutsui H, Momomura SI, Saito Y, Ito H, Yamamoto K, Sakata Y, Desai AS, Ohishi T, Iimori T, Kitamura T, Guo W. Efficacy and Safety of Sacubitril/Valsartan in Japanese Patients with Chronic Heart Failure and Reduced Ejection Fraction-Results From the PARALLEL-HF Study. Circ J. 2021;85(5):584-94. DOI:10.1253/circj.CJ-20-0854

Karim MA, Siddiqui HU, Ullah S, Khan NA. Sacubitril/Valsartan: Practice Changing Guideline in the Management of Congestive Heart Failure. J Coll Physicians Surg Pak. 2017;27(11):733-40.

Wu Y, Tian S, Rong P, Zhang F, Chen Y, Guo X, et al. Sacubitril valsartan compared with enalapril for the treatment of heart failure: A decision-analytic markov model simulation in China. Front Pharmacol. 2020;11:1101. DOI:10.3389/ fphar.2020.01101

Piepoli MF, Hussain RI, Comin Colet J, Dosantos R, Ferber P, Jaarsma T, Edelmann F. OUTSTEP HF: randomised controlled trial comparing short term effects of sacubitril valsartan versus enalapril on daily physical activity in patients with chronic heart failure with reduced ejection fraction . Eur J Heart Fail. 2021;23(1):127-35. DOI: 10.1002/ejhf.2076